- About the Series
- Performance Schedule
- News & Events
- Donate Now
Ryuji Ueno, M.D., Ph.D., Ph.D.
Dr. Ryuji Ueno is an internationally recognized researcher in pharmacology, physiology and the biochemistry of endogenic functional fatty acids and their related compounds. As a leading expert in his field, Dr. Ueno has authored more than 100 articles in notable scientific journals.
In the 1980s, Dr. Ueno started pharmaceutical development based on his research with prostones, a class of functional fatty acids whose tremendous therapeutic potential Dr. Ueno first identified. This class of lipids is the subject of over 650 patents worldwide, which are now exclusively held by the Sucampo Group. The Sucampo Group, co-founded by Dr. Ueno and Dr. Sachiko Kuno, is an international affiliation of pharmaceutical research, development and manufacturing companies.
After 10 years of biomedical research, Dr. Ueno, together with Dr. Kuno, established R-Tech Ueno, Ltd. in Japan, the first Sucampo Group company to engage in the research and development of new chemical substances discovered by him. The first product, Rescula®‚ an anti-glaucoma treatment, was commercialized in Japan in 1994. Today, Rescula® Eye Drops have been sold in more than 45 countries and have treated more than 500,000 patients.
Dr. Ueno, in partnership with Dr. Kuno, established Sucampo Pharmaceuticals, Inc. to bring his discoveries to the American markets. This led to the success of the second prostone product discovered by Dr. Ueno,, AMITIZA® (lubiprostone). At present, Dr. Ueno is Chief Executive Officer and Chairman of the Board of Sucampo Pharmaceuticals, Inc.
Dr. Ueno earned his M.D. and a Ph.D. in medicinal chemistry from Keio University (Tokyo) in Japan, and earned a Ph.D. in Pharmacology from Osaka University (Osaka). He conducted post-graduate research at Cold Spring Harbor Lab (New York) and Kyoto University (Kyoto) Department of Medicinal Chemistry.